Cargando…

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show immune evasion of vaccine-derived immunity, highlighting the need for better clinical immunogenicity biomarkers. To address this need, an enzyme-linked immunosorbent assay-based, human angiotensin-converting enzym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Massuda, Edmond, Patel, Urvashi, Klindworth, Andrew, Massare, Michael J., Cai, Rongman, Fries, Louis, Glenn, Greg, Kalkeri, Raj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965183/ https://www.ncbi.nlm.nih.gov/pubmed/36838333 http://dx.doi.org/10.3390/microorganisms11020368

Ejemplares similares

A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection
por: Zhu, Mingzhu, et al.
Publicado: (2023)

2753. Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Airuses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Seasonal Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2019)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2020)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses
por: Rydyznski Moderbacher, Carolyn, et al.
Publicado: (2022)

Angiotensin-converting enzyme: I. New strategies for assay
por: Ryan, James W., et al.
Publicado: (1980)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
por: Áñez, Germán, et al.
Publicado: (2023)

Review of Angiotensin-converting Enzyme Inhibitory Assay: Rapid Method in Drug Discovery of Herbal Plants
por: Ahmad, Islamudin, et al.
Publicado: (2017)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

A Convenient RP-HPLC Method for Assay Bioactivities of Angiotensin I-Converting Enzyme Inhibitory Peptides
por: Wang, Wei, et al.
Publicado: (2012)

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
por: Mallory, Raburn M, et al.
Publicado: (2022)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Strong CD4(+) T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination
por: Fries, Louis, et al.
Publicado: (2023)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19
por: Suresh, Vallabh, et al.
Publicado: (2023)

Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2019)

Discovery of new angiotensin converting enzyme (ACE) inhibitors from medicinal plants to treat hypertension using an in vitro assay
por: Sharifi, Niusha, et al.
Publicado: (2013)

Angiotensin-converting enzyme 2 and new insights into the renin–angiotensin system
por: Lambert, Daniel W., et al.
Publicado: (2008)

Angiotensin-Converting Enzyme 2: The First Decade
por: Clarke, Nicola E., et al.
Publicado: (2012)

Angiotensin-converting enzyme 2 in lung diseases
por: Kuba, Keiji, et al.
Publicado: (2006)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure
por: Patel, Vaibhav B., et al.
Publicado: (2012)

Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System
por: Trask, Aaron J., et al.
Publicado: (2009)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults
por: Kulkarni, Prasad S., et al.
Publicado: (2023)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Angiotensin-converting enzyme 2 expression is not induced by the renin–angiotensin system in the lung
por: Baba, Ryuta, et al.
Publicado: (2020)

Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
por: Jiang, Fan, et al.
Publicado: (2014)

Applying MAPPs Assays to Assess Drug Immunogenicity
por: Karle, Anette C.
Publicado: (2020)

Increased Urinary Angiotensin-Converting Enzyme 2 in Renal Transplant Patients with Diabetes
por: Xiao, Fengxia, et al.
Publicado: (2012)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Circulating angiotensin converting enzyme 2 and COVID-19
por: Leowattana, Wattana, et al.
Publicado: (2022)

Angiotensin-converting enzyme 2 in dogs with Dirofilaria immitis
por: Adin, Darcy B., et al.
Publicado: (2023)

Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme
por: Sharma, Urvashi, et al.
Publicado: (2020)

Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2
por: Clayton, Daniel, et al.
Publicado: (2015)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r568ns08dd9r0gdplsbgr25t6o